New drug aims to curb nosebleeds in rare bleeding disorder
Disease control
Ongoing
This study tests a new drug called VAD044 in 75 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and anemia. The goal is to see if the drug is safe and can reduce the number, length, and severity of nosebleeds. Participants firs…
Phase: PHASE1, PHASE2 • Sponsor: Vaderis Therapeutics AG • Aim: Disease control
Last updated May 08, 2026 12:03 UTC